| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
391,210,000 |
| Market
Cap: |
341.06(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.66 - $1.43 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.3 |
| Insider 6 Months : 4.3 |
| Insider 3/6 Months : 9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amarin a pharmaceutical company that focused on the commercialization and development of therapeutics to improve cardiovascular health. Co.'s primary product, Vascepa® (icosapent ethyl) capsules, is use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The U.S. Food and Drug Administration (FDA) approved an indication and label for Vascepa based on the results of Co.'s cardiovascular outcomes trial of Vascepa, REDUCE-IT® (Reduction of Cardiovascular Events with EPA – Intervention Trial). Vascepa is approved by the FDA as an adjunct to tolerated statin therapy for reducing persistent cardiovascular risk in select high risk patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
14,426 |
14,426 |
314,426 |
369,426 |
| Total Buy Value |
$15,724 |
$15,724 |
$328,039 |
$420,769 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
2 |
3 |
| Total Shares Sold |
0 |
34,131 |
34,131 |
34,131 |
| Total Sell Value |
$0 |
$26,963 |
$26,963 |
$26,963 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ketchum Steven B |
Chief Scientific Officer |
• – – |
2024-01-31 |
4 |
D |
$1.24 |
$51,072 |
D/D |
(41,187) |
658,720 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2024-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
79,500 |
681,036 |
|
- |
|
| Reilly Thomas Charles |
EVP and CFO |
• – – |
2024-01-31 |
4 |
D |
$1.24 |
$30,444 |
D/D |
(24,552) |
68,931 |
|
- |
|
| Reilly Thomas Charles |
EVP and CFO |
• – – |
2024-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
44,933 |
93,483 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2024-01-31 |
4 |
D |
$1.24 |
$50,619 |
D/D |
(40,822) |
633,260 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2024-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
79,500 |
655,214 |
|
- |
|
| Holt Patrick |
President and CEO |
• • – |
2024-01-22 |
4 |
B |
$1.09 |
$15,724 |
D/D |
14,426 |
314,426 |
0.01 |
-22% |
|
| Reilly Thomas Charles |
EVP and CFO |
• – – |
2024-01-10 |
4 |
D |
$0.97 |
$27,475 |
D/D |
(28,325) |
48,550 |
|
- |
|
| Reilly Thomas Charles |
EVP and CFO |
• – – |
2024-01-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,500 |
76,875 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2024-01-10 |
4 |
D |
$0.97 |
$27,368 |
D/D |
(28,214) |
594,582 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2024-01-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,500 |
622,796 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2024-01-10 |
4 |
D |
$0.97 |
$27,422 |
D/D |
(28,270) |
620,407 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2024-01-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,500 |
648,677 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2024-01-04 |
4 |
D |
$0.87 |
$13,450 |
D/D |
(15,460) |
571,296 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2024-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,133 |
586,756 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2024-01-04 |
4 |
D |
$0.87 |
$6,725 |
D/D |
(7,730) |
597,177 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2024-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,566 |
604,907 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2023-12-29 |
4 |
A |
$0.87 |
$20,467 |
D/D |
23,525 |
590,341 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2023-12-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,766 |
613,866 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2023-12-29 |
4 |
D |
$0.87 |
$20,467 |
D/D |
(23,525) |
557,623 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2023-12-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,766 |
581,148 |
|
- |
|
| Ketchum Steven B |
Chief Scientific Officer |
• – – |
2023-12-12 |
4 |
AS |
$0.79 |
$26,963 |
D/D |
(34,131) |
566,100 |
|
21% |
|
| Holt Patrick |
President and CEO |
• • – |
2023-08-16 |
4 |
B |
$1.03 |
$312,315 |
D/D |
300,000 |
300,000 |
0.01 |
-14% |
|
| Berg Aaron |
EVP, President US |
• – – |
2023-07-31 |
4 |
D |
$1.19 |
$13,998 |
D/D |
(11,763) |
533,382 |
|
- |
|
| Berg Aaron |
EVP, President US |
• – – |
2023-07-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,883 |
545,145 |
|
- |
|
578 Records found
|
|
Page 1 of 24 |
|
|
0.02 (2.69%) 
